Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764890 | 0.86 | ALDH1A1 (0.62) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL7970196 | 0.80 | RAB9A (0.51) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9480652 | 0.78 | ALDH1A1 (0.56) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL29515142 | 0.78 | ALDH1A1 (0.76) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1747868 | 0.78 | ALDH1A1 (0.53) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1976605 | 0.78 | ALDH1A1 (0.76) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL8135078 | 0.78 | L3MBTL1 (0.51) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL256024 | 0.77 | GABRP (0.61) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30154481 | 0.77 | GABRP (0.61) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL17321305 | 0.77 | ALDH1A1 (0.50) | ALDH1A1RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | ALDH1A1 1022/4885RAB9A 400/4885NPC1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.